The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), ZOETIS (NYSE:ZTS), McKesson Corp (NYSE:MCK).
The investment seeks long-term capital appreciation.
The fund seeks to achieve its objective by normally investing at least 80% of its net assets (plus borrowings made for investment purposes) in health sciences-related companies. The portfolio manager considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences. The fund will invest primarily in common stocks and other equity securities.
The average market capitalization across the Virtus KAR Health Sciences Inst MF is 184.15B. The market cap for tickers in the group ranges from 16.59B to 561.54B. LLY holds the highest valuation in this group at 561.54B. The lowest valued company is COO at 16.59B.
The average weekly volume growth across all stocks in the Virtus KAR Health Sciences Inst MF was -61%. For the same stocks of the MF, the average monthly volume growth was -70% and the average quarterly volume growth was -62%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 41
P/E Growth Rating: 48
Price Growth Rating: 50
SMR Rating: 53
Profit Risk Rating: 37
Seasonality Score: 10 (-100 ... +100)